Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels

Daichi Inoue, Masaki Matsumoto, Reina Nagase, Makoto Saika, Takeshi Fujino, Keiichi Nakayama, Toshio Kitamura

研究成果: ジャーナルへの寄稿記事

21 引用 (Scopus)

抄録

Recent progress in deep sequencing technologies has revealed many novel mutations in a variety of genes in patients with myelodysplastic syndromes (MDS). Most of these mutations are thought to be loss-of-function mutations, with some exceptions, such as the gain-of-function IDH1/2 and SRSF2 mutations. Among the mutations, ASXL1 mutations attract much attention; the ASXL1 mutations are identified in a variety of hematologic malignancies and always predicts poor prognosis. It was found that the C-terminal truncating mutants of the ASXL1 or ASXL1 deletion induced MDS-like diseases in mouse. In addition, it has recently been reported that ASXL1 mutations are frequently found in clonal hematopoiesis in healthy elderly people, who frequently progress to hematologic malignancies. However, the underlying molecular mechanisms by which ASXL1 mutations induce hematologic malignancies are not fully understood. Moreover, whether ASXL1 mutations are loss-of-function mutations or dominant-negative or gain-of-function mutations remains a matter of controversy. We here present solid evidence indicating that the C-terminal truncating ASXL1 protein is indeed expressed in cells harboring homozygous mutations of ASXL1, indicating the ASXL1 mutations are dominant-negative or gain-of-function mutations; for the first time, we detected the truncated ASXL1 proteins in two cell lines lacking the intact ASXL1 gene by mass spectrometry and Western blot analyses. Thus, together with our previous results, the present results indicate that the truncating ASXL1 mutant is indeed expressed in MDS cells and may play a role in MDS pathogenesis not previously considered.

元の言語英語
ページ(範囲)172-176.e1
ジャーナルExperimental Hematology
44
発行部数3
DOI
出版物ステータス出版済み - 3 1 2016

Fingerprint

Mutation
Neoplasms
Proteins
Myelodysplastic Syndromes
Hematologic Neoplasms
High-Throughput Nucleotide Sequencing
Hematopoiesis
Genes
Mass Spectrometry
Western Blotting
Technology
Cell Line

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

これを引用

Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. / Inoue, Daichi; Matsumoto, Masaki; Nagase, Reina; Saika, Makoto; Fujino, Takeshi; Nakayama, Keiichi; Kitamura, Toshio.

:: Experimental Hematology, 巻 44, 番号 3, 01.03.2016, p. 172-176.e1.

研究成果: ジャーナルへの寄稿記事

Inoue, Daichi ; Matsumoto, Masaki ; Nagase, Reina ; Saika, Makoto ; Fujino, Takeshi ; Nakayama, Keiichi ; Kitamura, Toshio. / Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. :: Experimental Hematology. 2016 ; 巻 44, 番号 3. pp. 172-176.e1.
@article{26d0d0a8bcb94ea498e628ef66e4b662,
title = "Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels",
abstract = "Recent progress in deep sequencing technologies has revealed many novel mutations in a variety of genes in patients with myelodysplastic syndromes (MDS). Most of these mutations are thought to be loss-of-function mutations, with some exceptions, such as the gain-of-function IDH1/2 and SRSF2 mutations. Among the mutations, ASXL1 mutations attract much attention; the ASXL1 mutations are identified in a variety of hematologic malignancies and always predicts poor prognosis. It was found that the C-terminal truncating mutants of the ASXL1 or ASXL1 deletion induced MDS-like diseases in mouse. In addition, it has recently been reported that ASXL1 mutations are frequently found in clonal hematopoiesis in healthy elderly people, who frequently progress to hematologic malignancies. However, the underlying molecular mechanisms by which ASXL1 mutations induce hematologic malignancies are not fully understood. Moreover, whether ASXL1 mutations are loss-of-function mutations or dominant-negative or gain-of-function mutations remains a matter of controversy. We here present solid evidence indicating that the C-terminal truncating ASXL1 protein is indeed expressed in cells harboring homozygous mutations of ASXL1, indicating the ASXL1 mutations are dominant-negative or gain-of-function mutations; for the first time, we detected the truncated ASXL1 proteins in two cell lines lacking the intact ASXL1 gene by mass spectrometry and Western blot analyses. Thus, together with our previous results, the present results indicate that the truncating ASXL1 mutant is indeed expressed in MDS cells and may play a role in MDS pathogenesis not previously considered.",
author = "Daichi Inoue and Masaki Matsumoto and Reina Nagase and Makoto Saika and Takeshi Fujino and Keiichi Nakayama and Toshio Kitamura",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.exphem.2015.11.011",
language = "English",
volume = "44",
pages = "172--176.e1",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels

AU - Inoue, Daichi

AU - Matsumoto, Masaki

AU - Nagase, Reina

AU - Saika, Makoto

AU - Fujino, Takeshi

AU - Nakayama, Keiichi

AU - Kitamura, Toshio

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Recent progress in deep sequencing technologies has revealed many novel mutations in a variety of genes in patients with myelodysplastic syndromes (MDS). Most of these mutations are thought to be loss-of-function mutations, with some exceptions, such as the gain-of-function IDH1/2 and SRSF2 mutations. Among the mutations, ASXL1 mutations attract much attention; the ASXL1 mutations are identified in a variety of hematologic malignancies and always predicts poor prognosis. It was found that the C-terminal truncating mutants of the ASXL1 or ASXL1 deletion induced MDS-like diseases in mouse. In addition, it has recently been reported that ASXL1 mutations are frequently found in clonal hematopoiesis in healthy elderly people, who frequently progress to hematologic malignancies. However, the underlying molecular mechanisms by which ASXL1 mutations induce hematologic malignancies are not fully understood. Moreover, whether ASXL1 mutations are loss-of-function mutations or dominant-negative or gain-of-function mutations remains a matter of controversy. We here present solid evidence indicating that the C-terminal truncating ASXL1 protein is indeed expressed in cells harboring homozygous mutations of ASXL1, indicating the ASXL1 mutations are dominant-negative or gain-of-function mutations; for the first time, we detected the truncated ASXL1 proteins in two cell lines lacking the intact ASXL1 gene by mass spectrometry and Western blot analyses. Thus, together with our previous results, the present results indicate that the truncating ASXL1 mutant is indeed expressed in MDS cells and may play a role in MDS pathogenesis not previously considered.

AB - Recent progress in deep sequencing technologies has revealed many novel mutations in a variety of genes in patients with myelodysplastic syndromes (MDS). Most of these mutations are thought to be loss-of-function mutations, with some exceptions, such as the gain-of-function IDH1/2 and SRSF2 mutations. Among the mutations, ASXL1 mutations attract much attention; the ASXL1 mutations are identified in a variety of hematologic malignancies and always predicts poor prognosis. It was found that the C-terminal truncating mutants of the ASXL1 or ASXL1 deletion induced MDS-like diseases in mouse. In addition, it has recently been reported that ASXL1 mutations are frequently found in clonal hematopoiesis in healthy elderly people, who frequently progress to hematologic malignancies. However, the underlying molecular mechanisms by which ASXL1 mutations induce hematologic malignancies are not fully understood. Moreover, whether ASXL1 mutations are loss-of-function mutations or dominant-negative or gain-of-function mutations remains a matter of controversy. We here present solid evidence indicating that the C-terminal truncating ASXL1 protein is indeed expressed in cells harboring homozygous mutations of ASXL1, indicating the ASXL1 mutations are dominant-negative or gain-of-function mutations; for the first time, we detected the truncated ASXL1 proteins in two cell lines lacking the intact ASXL1 gene by mass spectrometry and Western blot analyses. Thus, together with our previous results, the present results indicate that the truncating ASXL1 mutant is indeed expressed in MDS cells and may play a role in MDS pathogenesis not previously considered.

UR - http://www.scopus.com/inward/record.url?scp=84960098133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960098133&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2015.11.011

DO - 10.1016/j.exphem.2015.11.011

M3 - Article

C2 - 26700326

AN - SCOPUS:84960098133

VL - 44

SP - 172-176.e1

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 3

ER -